Journal
NEUROSCIENCE BULLETIN
Volume 32, Issue 4, Pages 389-397Publisher
SPRINGER
DOI: 10.1007/s12264-016-0037-6
Keywords
Major depressive disorder; Epidemiology; Antidepressant; Pathogenesis; Biomarker; China
Categories
Funding
- National Natural Science Foundation of China [81371488, 81571330]
Ask authors/readers for more resources
Depression is the most disabling disorder worldwide that accounts for the highest proportion of global burden attributable to mental disorders. Major depressive disorder (MDD) is characterized by deep sadness, reduced energy, vegetative nervous system dysregulation, cognitive dysfunction, and even a high suicidal tendency. Although other treatment choices are available, antidepressant medication is the front-line treatment option for MDD. Regarding clinical efficacy, only similar to 50% of patients respond to frontline antidepressants, and < 33% obtain remission. Currently, objective indexes to guide clinical decisions are still lacking. Furthermore, knowledge about the neurobiological mechanisms underlying discrepant antidepressant outcomes is still also fragmentary. In the present review, we discuss the current research progress and clinical opinions on MDD in China.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available